저니 메디컬DERM 주가

Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?

Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. Read more on FBIO stock here.

Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference

SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Confere

♻️ 재탕Journey Medical Corporation Q1 2026 Earnings Call Summary

Moby summary of Journey Medical Corporation's Q1 2026 earnings call

Journey Medical Corp (DERM) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

Journey Medical Corp (DERM) reports strong revenue growth and strategic partnerships, despite facing margin pressures and reimbursement challenges.

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings

The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

♻️ 재탕Journey Medical (DERM) Q1 2026 Earnings Transcript

Joining me from Journey Medical's leadership team are Claude Maraoui, Co Founder, President and Chief Executive Officer Joseph Benesch, Chief Financial Officer and Ramsey Alloush, Chief Operating Officer and General Counsel. During this call, management will be making forward looking statements including statements that address, among other things, Journey expectations for future performance, operational results, financial condition and the receipt of regulatory approvals. For more information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q, the Form 8-K filed with the SEC today, the company's press release that accompanies this call.

♻️ 재탕Transcript: Journey Medical Q1 2026 Earnings Conference Call

Journey Medical (NASDAQ:DERM) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. The full earnings call is available at https://event.choruscall.com/mediaframe/webcast.html?webcastid=RrRNlbZT Summary Journey Medical reported a 21% year-over-year increase in total net p

Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates

Journey Medical (DERM) delivered earnings and revenue surprises of -14.29% and +5.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corp (NASDAQ:DERM) Slightly Misses Q1 2026 Revenue Expectations as Stock Rises on Strong Emrosi Growth and Full-Year Profitability Outlook

Journey Medical (DERM) Q1 2026 revenue rose 21% to $16M, slightly missing estimates. Stock gained 5.9% after-hours on strong Emrosi sales and full-year profitability expectations.

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical compan